Preparation and evaluation of tamsulosin hydrochloride sustained-release pellets modified by two-layered membrane techniques  by Wang, Jingmin et al.
w.sciencedirect.com
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 3 1e3 9HOSTED BY Available online at wwScienceDirect
journal homepage: ht tp: / /ees.e lsevier .com/ajps/defaul t .aspOriginal Research PaperPreparation and evaluation of tamsulosin
hydrochloride sustained-release pellets modified
by two-layered membrane techniquesJingmin Wang, Yinghua Sun, Bo Li, Rui Fan, Bing Li, Tengrui Yin,
Ling Rong, Jin Sun*
Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, Chinaa r t i c l e i n f o
Article history:
Received 21 April 2014
Received in revised form
20 July 2014
Accepted 7 August 2014
Available online 28 August 2014
Keywords:
Preparation
In vitro evaluation
Tamsulosin hydrochloride
Sustained-release pellets
Drug release mechanism
Stability study* Corresponding author. Shenyang Pharmace
fax: þ86 24 23986320.
E-mail address: sunjin0529@aliyun.com (J. S
Peer review under responsibility of Shenyan
http://dx.doi.org/10.1016/j.ajps.2014.08.009
1818-0876/© 2015 Shenyang Pharmaceuticala b s t r a c t
The aim of the present study was to develop tamsulosin hydrochloride sustained-release
pellets using two-layered membrane techniques. Centrifugal granulator and fluidized-
bed coater were employed to prepare drug-loaded pellets and to employ two-layered
membrane coating respectively. The prepared pellets were evaluated for physicochem-
ical characterization, subjected to differential scanning calorimetry (DSC) and in vitro
release of different pH. Different release models and scanning electron microscopy (SEM)
were utilized to analyze the release mechanism of Harnual® and home-made pellets. By
comparing the dissolution profiles, the ratio and coating weight gain of Eudragit® NE30D
and Eudragit® L30D55 which constitute the inside membrane were identified as 18:1 and
10%e11%. The coating amount of outside membrane containing Eudragit® L30D55 was
determined to be 0.8%. The similarity factors (f2) of home-made capsule and commercially
available product (Harnual®) were above 50 in different dissolution media. DSC studies
confirmed that drug and excipients had good compatibility and SEM photographs showed
the similarities and differences of coating surface between Harnual® and self-made pellets
before and after dissolution. According to Ritger-Peppas model, the two dosage form had
different release mechanism.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Tamsulosin hydrochloride (TSH), as a model drug, is a highly
selective a1A-adrenoreceptor antagonist. It has been devel-
oped to treat lower urinary tract symptoms suggestive ofutical University, No. 103
un).
g Pharmaceutical Univer
University. Production anbenign prostatic hyperplasia (LUPS/BPH) [1]. It is reported that
TSH is absorbed rapidly and completely in intestinal and
eliminated slowly after oral administration, which may bring
many adverse effects. Therefore TSH is a perfect candidate
drug formodified-release dosage form tomodulate the release
rate of drug and the absorption in GIT [2]., Wenhua Road, Shenyang 110016, China. Tel.: þ86 24 23986325;
sity.
d hosting by Elsevier B.V. All rights reserved.
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extensively in sustained-release (SR) formulations. Compared
with conventional single-unit drug delivery system, pellets
are believed to represent many bio-pharmaceutical advan-
tages. For example, pellets can homogeneously distribute in
gastrointestinal (GIT), increase the contact area between drug
and GIT, decrease local drug concentration and irritation, and
provide stable plasma profiles and high bioavailability. In
addition, pellets are more reproducible and repeatable
because of its small unit, especially in the stomach [3].
The release homogeneity of commercial product Harnual®
was not good because of the particle size distribution of its
pellets. To overcome the defect, we employed a different
preparation craft to prepare uniform drug-loaded pellets and
we gained a formulation with nice release homogeneity. The
self-made TSH sustained-release (SR) pellets consist of uni-
form blank pellets, the layer of drug-loading and two-layered
coating membranes. So far, there are many approaches to
make SR formulations [4e8]. In our study, centrifugal granu-
lator was employed to prepare blank pellets and drug-loading
pellets while fluidized-bed coater was used for coating.
Considering the lower toxicity and less environmental
concern, aqueous polymeric dispersions were chosen as
coating materials. In general, through varying the type or
weight gain of coating material, we could achieve the desired
release profile. However, one single type aqueous polymer
dispersion is not enough to produce a wonderful drug release
behavior sometimes. Binary blends of polymers were pro-
posed to make up the defect. This technique can not only
provide broad range of drug release patterns, but also improve
film thermo-sensitivity [9]. Eudragit® NE30D and Eudragit®
L30D55 were utilized as the inside coating material to achieve
a particular pH-sensitive release [10,11]. Eudragit® L30D55, as
the enteric coating material, can prohibit drug release in the
simulated gastric fluid and easily be dissolved in the intestinal
environment as pore-forming agents, which is also the reason
for selecting Eudragit® L30D55 as the outside coating polymer
[3]. The model of TSH SR pellets is depicted as Fig. 1.Table 1 e The optimized parameters of centrifugal
granulator for the preparation of blank pellets.2. Materials and methods
2.1. Materials
TSH (99.8% purity) was purchased from Zhejiang Jinhua
pharmaceutical Co., Ltd (Zhejiang, China), Microcrystalline
cellulose (MCC) (Avicel PH101) was purchased from Huzhoublank pellet
drug-loaded layer
the inside membrane
the outside membrane
Fig. 1 e The model of TSH SR pellet.Zhanwang Pharmaceutical Co., Ltd, (Huzhou, China), HPMC
was a gift from Shanhe Pharmaceutical Co., Ltd, (Anhui,
China), methacrylic acid copolymers (Eudragit® NE30D and
Eudragit® L30D55) were kindly provided by Degussa (Esson,
Germany), No. 3 hard gelatin capsules were purchased from
Suzhou Capsule Co. (Suzhou, China), Commercially available
controlled-release TSH capsule (Harnal, 0.2 mg/capsule,
Yamanouchi Pharmaceutical Co. Ltd., Japan) was chosen for
comparison. All organic solvents were of high-performance
liquid chromatography (HPLC) grade. All other chemicals
were of analytical grade.
2.2. Methods
2.2.1. Drug-excipient interaction studies
Differential scanning calorimetry (DSC) was used to investi-
gate the possibility of drug-excipient interaction. Pure drug,
the mixture of excipients and drug-excipient mixtures were
separately sealed in aluminum cells at a heating rate of 10 C/
min in a nitrogen atmosphere over a temperature range of
30e300 C. Alumina was utilized as the reference standard.
2.2.2. The preparation of blank pellets
Centrifugal granulator was chosen to prepare blank pellets
and subsequent drug spraying. The particle size distribution
of blank pellets is 0.3e0.4 mm. Pelletization by centrifugal
granulator is an advanced technique. Being a multivariable
process, it is of great significance to know and control the
process variables and status. Rotational speed of plate, the
ratio of spray rate of binding solution and rotating rate of
powder feeder and grounding time were found to be critical
parameters affecting the characteristics of pellets. Table 1
denotes the optimized process parameters.
400 g microcrystal cellulose (MCC) was loaded into the
chamber of centrifugal granulator, then moistened with pu-
rified water. Adding MCC via a hopper to the above wet mass
after 10 min wetting. In the process, we must keep all the
parameters constant. The pellets need to be granulated for
another 4min even though the particle size distributionmeets
our requirement. The final products were discharged from the
chamber and half-dry in the room temperature. Then, the
pellets were placed into oven of 60 C for 2 h. Finally, sieving
the pellets through 40e50 mesh screen.Processing parameter Value
Rotational speed of plate 200 r/min
Blower rate 10  14 L/min
Air flow rate 10 L/min
Spray air pressure 0.6 MPa
Spray rate of binding solutiona 3e5 g/min
Rotating rate of powder feederb 0e15 r/min
Inlet temperature (C) 30
Outlet temperature (C) 20
a The spray rate was 5 g/min for the first 15 min, and subsequently
3 g/min until the end.
b The rotating rate of powder feeder was 0 r/min for the first
15 min, and subsequently 15 r/min until the end.
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TSH SR capsule contains 0.2 mg active ingredient which oc-
cupies 0.13% to the whole dosage form. TSH was dissolved to
solution and sprayed to blank pellets homogeneously to meet
the requirement of content uniformity. Firstly, desired tween-
80 (2.3%, wt/wt, based on the solution) was weighed and put
into 1000 ml distilled water, adding TSH to the above solution,
then sonicating for 10min, standby for 5min, which goes for 3
times again and again until the TSH dissolved entirely.
Hydroxypropylmethylcellulose (HPMC) (0.8%, wt/wt, based on
the solution) was added to 1000 ml purified water which had
been heated to 50 C previously, stirring constantly until it
fully dissolved. Pouring the above solution into drug solution
when it cools down to room temperature. Mixing for 5 min
and laying aside. The amount of drug and excipients must
strictly comply with the drug solution formulation. The pro-
cessing parameters were the same as the preparation of blank
pellets except Spray rate of drug solution (3 g/min) and
Rotating rate of powder feeder (The rotating rate of powder
feeder was 0 r/min for the first 5 min, and subsequently 8 r/
min until the end). Through adjusting the ratio of drug solu-
tion and MCC powders, we could avoid the agglomeration of
pellets.
2.2.4. Coating of TSH sustained-release pellets
The operating procedure of inside coating material was as
follows: Shaking the polymer dispersions every time before
using to promise reproducibility. The desired amount of
Eudragit® NE30D was stirred by a magnetic stirrer, dispersing
micronized talc (55%, wt/wt, based on the dry polymerweight)
in distilled water which is the same amount as Eudragit®
NE30D polymer dispersion with a high-speed disperser for
5 min. The talc solution was poured into the above Eudragit®
NE30D solution, making the total coating suspension with a
solid content of 15%. Eudragit® L30D55 and the same amount
of purified water were weighed respectively and mixed.
Triethyl citrate (TEC) (20%, wt/wt, based on dry polymer
weight) was added to the mixture, stirring sufficiently. Then
Eudragit® L30D55 was blended with Eudragit® NE30D under
the magnetic stirrer. Mixing for 30 min and laying aside.
The outside coating material was very simple. As
mentioned above, desired Eudragit® L30D55 was weighed and
stirred with a magnetic stirrer. Micronized talc (20%, wt/wt,
based on dry polymer weight) was dispersed in the distilled
water which was also the same amount as Eudragit® L30D55.
Adding the talc solution prepared above and desired TEC (20%,
wt/wt, based on dry polymer weight) to Eudragit® L30D55
dispersion under stirring. Mixing for 10 min and standby.
In the coating process, the coating dispersion must be
stirred continuously. After the inside coating, Talc (1%, wt/wt,
based on pellets) wasmixedwith pellets to avoid tack problemTable 2 e The physical parameters of three batches of pellets.
Characteristics
Percentage yield (%) Angle of
1 85.2 ± 0.2 20.2
2 85.4 ± 0.1 21.5
3 85.5 ± 0.1 23.4before moving into the oven and cured for 20 h at 40 C. The
outside coating was just need curing for 2 h without blending
with anything.
Coating conditions: air source pressure: 5.2 bar, atomiza-
tion pressure: 1.8 bar, inlet temperature: 25 C, outlet tem-
perature 20 C,material temperature 25 C, air flow: 60e70m3/
h, spray rate: 6 g/min.
2.2.5. Study of characteristics of prepared pellets
Three batches of qualified products were measured to deter-
mine the characteristics of pellets, such as Percentage Yield of
pellets, angle of repose, friability. Table 2 summarized the
physical parameters of three batches of pellets. The actual
Percentage Yields of pellets were calculated by the following
formular (1).
Percentage yield of pellets ¼ Practical yield of pellets
Theoretical yield of pellets
(1)
The fixed base cone method was utilized to evaluate the
angle of repose of pellets. A funnel was fixed at 1 cm above the
horizontal flat surface until the apex of the conical pile just
touched to the tip of the funnel, allowing the pellets to fall
freely. Measuring the height and diameter of the cone and
calculating the angle of repose by the following formular (2).
q ¼ tan1h
r
(2)
where h, r expresses the Height of pile and the Radius of pile,
respectively.
The friability of the pellets were determined as % weight
lossafter 100 revolutionsof 10gofpellets in a friabilator [12,13].
2.2.6. Determination of drug content
The drug content was measured by the method of HPLC. The
HPLC system consisted of a chromaster 5110 pump and
chromaster 5410 detector (HITACHI chromaster Japan). A
Thermo C18 reverse-phase column (5 mm, 150  4.6 mm) was
fitted in a column oven with the temperature of 40 C. The
mobile phase was made up of acetonitrile and perchloric acid
(dissolve 8.7 ml of perchloric acid and 3.0 g of sodium hy-
droxide in 1900 ml distilled water. Adjust with 1N sodium
hydroxide to a pH of 2.0, and add sufficient water to 2000 ml)
with the ratio of 31:69 (v/v). The injection volume was 10 ml,
the flow rate was 1.3 ml/min, and the UV detector wavelength
was set at 225 nm.
From each batch of coated pellets, fine powders which
were ground previous with a mortar and pestle were accu-
rately weighed (equivalent to approximately 0.5 mg TSH) and
placed into a 25 ml volumetric flask. 10 ml NaOH solution
(0.05mol/l) was added, then putting the flask into a water bath
which had been heated to 50 C for 10 min, shaking well. TheBatch
repose (q) Friability (%) Drug content (%)
± 0.8 0.07 ± 0.01 99.8 ± 0.2
± 0.6 0.06 ± 0.03 99.5 ± 0.3
± 1.5 0.07 ± 0.02 100.2 ± 0.1
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temperature, the solution was diluted with miscible liquids of
HCl solution (0.2 mol/l) and acetonitrile (1:5). Sonicated again,
until the drug was dissolved completely. The drug solution
was centrifuged at 3500 r/min for 5 min, passing the super-
natant liquid through a 0.45-mm membrane filter. The filtrate
was then analyzed by HPLC [14].
2.2.7. Drug release measurements and comparisons
In vitro drug dissolution test was performed using USP XXVII
Type 2 dissolution apparatus (paddles method). Before the
test, 500 ml simulated gastric fluid (SGF) without pepsin
(withdraw 5.7 ml HCl to 1000 ml purified water, and add 2 g
NaCl) containing polysorbate 80 (0.003%, wt/wt) was put into
dissolution containers of a ZRS-8G Test Dissolution Tester
(Tianjin University Radio Factory, Tianjin, China) which could
keep the solution at 37 ± 0.1 C. Then the TSH SR capsule
equivalent to 0.2 mg TSH with a sinker was placed into it,
meanwhile, rotating speed of paddles was setted at 100 r/min.
At 2 h after the start of the test, withdrawing 10.0 ml of the
solution under test. Draining the SGF with the help of a 100-
mesh screen and rinsing the screen while adding the simu-
lated intestinal fluid (pH 7.2, phosphate buffer) previous
warmed, then continue the test. At each predetermined time
point, 10.0 ml of the solution was withdrawn and replaced by
the same volume of fresh solution until 4 h (in the simulated
intestinal fluid). All the sample solutionswere filtered through
0.22 mm filtration membrane and analyzed by HPLC as the
assay of drug content, with the injection volume of 20 ml [14].
In vitro dissolution test could reflect the drug release ki-
netics in vivo. In order to better evaluate the similarity be-
tween home-made capsule and Harnual®, different pH of
phosphate buffer as dissolutionmediumwere employed, such
as 5.0, 5.5, 6.2, 6.8 and water.
As the tool of similarity evaluation, the similarity factor (f2)
plays an important role in the comparison of dissolution
profiles. f2 is a logarithmic transformation of the sum-squared
error of differences between the test and reference product
over all time points [15]:
f2 ¼ 50 log
("
1þ 1
n
Xn
t¼1
ðRt  TtÞ2
#1=2
 100
)
where log indicates logarithm based on 10. It is suggest that
two dissolution profiles can be concluded to be similarity
when f2 value is more than 50. Generally, only one time point
can be used to calculate f2 with the release amount reaching
85%.
2.2.8. Scanning electron microscopy
To evaluate the coating surface of coating polymer mem-
brane, scanning electron microscopy (SEM, ZEISS, Carl Zeiss
Jena) images were achieved from the pellets of Harnual® and
self-made before and after dissolution. For further analyzing
the drug release mechanisms, the pictures were taken at
magnification of 400.
2.2.9. Drug release mechanism
It was concluded that there were three possible pathways for
drug release from the inside of polymeric membrane tooutsidemedium: (1) the drug distributed inside themembrane
and migrated into the consistent polymeric network, then
redistributed in the framework and dispersed to the outside
medium; (2) the drug dispersed to outside medium through
tiny holes or cracks on the membrane; (3) the coalesces of the
above two [16e18]. All kinds of mathematical models were
put forward to study the dissolution behavior in vitro including
zero-order [19], first-order [20], Higuich model [21], Hixsone-
Crowell model and BakereLonsdale model [22]. By linear or
nonlinear least-squares fitting methods, the optimum values
of the parameters expressed in each equation were obtained.
Regression analysis was carried out and best fits were calcu-
lated on the basis of correlation coefficient as r2.
In addition, for further analysis of drug release mecha-
nism, Ritger-Peppas model [23] was used. The equation of
Ritger-Peppas model was the following formular (3). Qt
expressed the accumulation release at time t, K denotes the
release rate constant. n is the special parameter describing the
release mechanism. If “n”  0.45, the mechanism of drug
release was Fick-diffusional. If 0.45 ＜ “n” ＜ 0.89, the drug
release mechanism was non-Fick dispersion including Fick-
diffusional and relaxation. If the “n”0.89, only the relaxa-
tion played the main role in drug release.
ln Qt ¼ n ln tþ K (3)
2.2.10. Stability study
Put the home-made pellets into the condition of high tem-
perature (40 C, 60 C), high humidity (RH 75%, RH 92.5%) and
light (4500 ± 500) Lx for 10 d. Take out the sample at 5 d and
10 d respectively. Inspect the contents, related substances and
dissolution release of samples.3. Results and discussion
3.1. Drug-excipient interaction by differential scanning
calorimetry (DSC)
DSC curves obtained for TSH, mixture of excipients and drug-
excipients mixture are shown in Fig. 2. The DSC thermogram
for TSH showed a sharpmelting endothermic peak at 233.2 C.
The mixture of excipients did not show any characteristic
peaks. There was no shift in the endothermic peak of TSH in
the drug-excipients mixture, indicating good compatibility of
the drug with all the excipients.
3.2. Effect of processing parameters of centrifugal
granulator on the preparation of blank pellets
As stated above, rotational speed of plate/the ratio of spray
rate of binding solution and rotating rate of powder feeder/
grounding time were processing parameters, which have po-
tential influence on the morphologic characteristic and
rheological parameters of pellets. In our study, a 33 full
factorial design was used to optimize the processing variables
[16]. The responses studied were the yield of 0.3e0.4 mm pel-
lets, angle of repose, friability, surface roundness. In general,
fixing other variable quantities, the particle size of pellets
decreased with the increase of rotational speed of plate. The
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Fig. 2 e Differential scanning calorimetry curves for blank
excipients, drug and physical mixture.
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Fig. 3 e A. Release profiles of TSH SR pellets coated by
different concentrations of coating solution; B. the release
profiles of TSH SR pellets influenced by the ratio of
Eudragit® NE30D and Eudragit® L30D55; C. Release profiles
of TSH SR pellets affected by coating thickness (each point
represents the mean ± SD, n ≥ 3).
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powder feeder was of great importance to the yield of pellets.
The particle size of pellets and the agglomeration condition of
pellets would increase when the ratio was much higher. In
contrast, the pellets would not grow up and MCC powders
became superfluous. With the increase of grounding time, the
particle size distribution tended to be wider and shift to large
size. In addition, the bulk intensity and sphericity were
increased, meanwhile, the friability was decreased. The
grounding time had few influence on the angles of repose. The
optimized processing parameterswere determined as follows:
rotational speed of plate: 200 r/min, the ratio of spray rate of
binding solution and rotating rate of powder feeder is 1:1,
grounding time: 4 min.
3.3. Inspect of the amount of tween-80 and HPMC in
TSH solution
TSH was slightly soluble in water, thus, tween-80, as solubi-
lizing agent, was added to the drug solution. Separating out
crystals or not was chosen as the evaluation standard to
determine the formulation amount of tween-80. 2.0%, 2.3%,
2.5% tween-80 was added to 2000 ml TSH solution respec-
tively, and sonicated for 10 min in parallel, laid aside for
10 min, which was performed in triplicate. The result sug-
gested that some drug crystals were still undissolved when
2.0% tween-80 was added. However, 2.3% and 2.5% tween-80
both made the TSH solution to be transparent. Finally, 2.3%
tween-80 was confirmed to the last formulation quantity.
In the process of drug spraying, HPMC played the role of
adhesion, so it could cohere the MCC powders drying the drug
pellets in time to blank pellets. Different concentrations of
HPMC solution including 0.5%, 0.8%, 1.0% were prepared to
evaluate their influence on the procedure. MCC powders
became small particles by itself under the spraying of 0.5%
HPMC solution resulting in low drug-loading capacity. The
viscosity of 1.0% HPMC solution was high enough to agglom-
erate the blank pellets on the bottom of centrifugal granulator
so that the spraying process could not go on smoothly. How-
ever, 0.8% HPMC solution could avoid the above problems and
made the industrial manufacture into reality.3.4. The temperature and relative humidity of
environment for coating
The coating temperature not only influences the coating
process, but also determines the quality of membrane. In
general, 10e20 C was demanded over the minimum
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 3 1e3 936membrane formation temperature. Too high or low temper-
ature could affect the intact of the membrane and change the
drug release behavior consequently. Eudragit®NE30D requires
coating temperature at 22e25 C, and the highest temperature
was 28 C which made the pellets agglomeration during
coating. In our experiment, we controlled the inlet tempera-
ture at 25 C and the outlet temperature at 20 C.
Relative humidity was another significant factor affecting
coating procedure. Static electricity would be produced be-
tween pellets and chamber wall of fluidized-bed coater when
the relative humidity was too low, resulting in nonuniform
coating. Pellets would be agglomerated under the high relative
humidity, changing the pellets' condition of circulation. The
coating process will be performed successfully under the
30%e50% relative humidity of the environment around ac-
cording to experience.
3.5. Effect of concentration of aqueous polymer
dispersions on drug release and coating process
Generally, aqueous polymer dispersions contain 30% solid
polymers. The dispersions need to be diluted to appropriate
concentration before coating. In our study, 10%, 15%, 20%0 20 40 60 80 100 120
0
20
40
60
80
100
120
Uncoated pellets
A
cc
um
ul
at
iv
e 
re
le
as
e(%
)
Time(min)
A
0 1 2 3 4 5 6
0
20
40
60
80
100
A
cc
um
ul
at
iv
e 
re
le
as
e(%
)
Time(h)
 one-layer coated pellets
 two-layer coated pellets
 Harnual
B
Fig. 4 e The dissolution profiles of uncoated pellets, one-
layer coated pellets, two-layers coated pellets, Harnual®
(A: uncoated pellets; B: one-layer coated pellets, two-layers
coated, Harnual®, each point represents the mean ± SD,
n ≥ 3).aqueous dispersion were prepared to explore the effect of
concentration of coating solution on the drug release and
coating process. 10% and 15% coating solution both could
complete the coating successfully, nevertheless, the concen-
tration of 10% consumesmuchmore time to gain the identical
coating level. The pellets appeared to conglutinate under the
spraying of 20% aqueous dispersion, which could notmeet the
requirement of production in industrial-scale. Therefore, we
usually dilute the aqueous polymer dispersion to 15%. Under
the same coating parameters, the pellets with the equal
coating level represent the consistent release kinetics even
through the concentration of coating dispersion is different.
Fig. 3A expressed the dissolution profiles of TSH SR pellets
coated by different concentrations of coating solutions.3.6. Effect of the ratio of Eudragit® NE30D and
Eudragit® L30D55 on the release of TSH SR pellets
Different ratios of Eudragit® NE30D and Eudragit® L30D55
were prepared containing 15:1, 18:1 and 20:1. A batch drug-
load pellets which was divided into triplicate were coated by
the different coating materials with the same coating level.0 1 2 3 4 5 6
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Fig. 5 e The dissolution profiles of home-made capsule and
marketed one in different pH: (A) marketed one, (B) home-
made capsule (each point represents the mean ± SD, n ≥ 3).
Table 3 e The f2 of dissolution profiles of
home-made capsule and marketed one in
different dissolution medium.
Medium f2
Water 75
PH 5.0 52
PH 5.5 58
pH 6.2 48
PH 6.8 51
PH 7.2 62
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three baches of TSH SR pellets. The experimental result
manifested that few difference was appeared for the first 2 h
of dissolution release. However, the last 4 h of drug dissolution
in the simulated intestinal fluid presented huge differences.
With increase of the amount of Eudragit® NE30D, the accu-
mulative release decreased. The release amount of drug is
much lower than Harnual® with the ratio of 20:1. Finally, the
ratio of 18:1 was chosen by comprehensive analysis. Fig. 3B
denoted the release profiles of TSH SR pellets influenced by
the ratio of Eudragit® NE30D and Eudragit® L30D55.
3.7. Effect of film thickness on drug release
The ratio of Eudragit® NE30D and Eudragit® L30D55 was
controlled at 18:1 and some coated pellets were taken out
from discharge hole of fluidized-bed coater respectively when
the coating weight gain reached to 7%, 10%, 12%. As can be
seen, the accumulative release was significantly decreasedFig. 6 e A1, B1 express the coating surface of pellets before disso
(A: Harnual®, B: home-made).with the increase of coating amount because of the increased
diffusion path length. The drug was released entirely at 3 h
with 7% coating amount, thus, the membrane did not play the
role of prolonging drug release. When the coating weight gain
reached to 12%, the accumulative release was near to Haru-
nal® except to the first 2 h. After coating the outside mem-
brane, the release rate would decrease overall compared with
the commercially available product. Therefore, we controlled
the coating weight gain at the range of 10%e11%. Fig. 3C
depicted the effect of the coating thickness on drug release.3.8. In vitro dissolution testing
3.8.1. The release profiles of uncoated pellets, one-layer
coated pellets, two-layer coated pellets and Harnual®
Fig. 4A represented the dissolution profile of uncoated pellets.
We could conclude that the drug was dissolved completely at
about 30 min and the dissolution would not be influenced by
the solubility of drug. The release amount of one-layer coated
pellets was a little higher than Harnual® and the two-layer
membranes coated pellets had the same release behaviorwith
the marketed products, as shown in Fig. 4B. The reason was
that pellets were agglomerated together by Eudragit® L30D55
at the first 2 h of the dissolution test, reducing the contacting
area between pellets and dissolution medium. Therefore, the
release amount was decreased notably in the SGF.
3.8.2. Drug release comparison
The release profiles of self-made capsule and Harnual® were
compared in different dissolution medium. From the dissolu-
tion result, we could reach a conclusion that the home-madelution; A2, B2 express the surface of pellets after dissolution
Table 4 e Models of drug release and correlation
coefficients.
Model Equation r
Harnual® Self-made
Zero-order model Qt ¼ k0t 0.9738
0.9781
0.9325
First-order model ln (Q0  Qt) ¼ k1t
þ lnQ0
0.9937 0.9941
Higuchi diffusion
model
Qt ¼ kH t1/2 0.9831 0.9498
Ritger-Peppas
model
ln Qt ¼ n lnt þ k 0.9788 0.9456
HixsoneCrowell
model
(1  Qt)1/3 ¼ 1  kt 0.9945 0.9795
BakereLonsdale
model
3/2[1(1  Qt)2/3]
Qt ¼ kt
0.9960 0.9871
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water. While, the accumulation release of self-made capsule
was a little higher than Harnual® in the dissolutionmediumof
5.0, 5.5, 6.2. The two dosage forms were similar through
comparing the f2 of dissolution profiles in different pH
(expressed in the Table 3). The dissolution profileswere shown
in Fig. 5.
3.9. SEM experiments
SEM images of dry pellets before and after dissolution are
shown in Fig. 6. From A1, B1 photos we can conclude that the
market product and self-made pellets are both have smooth
coating surface with a few pores before dissolution. Many
pores appeared after dissolution which can be seen from A2.Table 5 e Stability of f1 exposed to different conditions.
Condition Time
(day)
Content
character
Related
substances (%)
(before the main drug)
0 White-pellets
No bounded
14.30
40 C 5 White-pellets
No bonded
36.63
10 White-pellets
No bonded
27.04
60 C 5 White-pellets
Some bonded
26.46
10 White-pellets
Some bonded
36.83
75% 5 White-pellets
No bonded
30.38
10 White-pellets
Some bonded
14.50
92.5% 5 White-pellets
Some bonded
17.37
10 White-pellets
bonded
39.89
Light (4500 ± 500)Lx 5 White-pellets
No bonded
34.38
10 White-pellets
No bonded
32.00Compared with market product, the appearance of self-made
pellets which can be seen from B2was rough and some cracks
appeared. This may contribute to different preparation graft
in the two dosage forms.3.10. The mechanism of drug release
As shown in Table 4, First-order model, HixsoneCrowell
model and BakereLonsdalemodel were all fitted for Harnual®,
and BakereLonsdale model was the best fitted one. The result
demonstrated that both free diffusion and relaxation played
important role in the drug release of marketed product. First-
order model, BakereLonsdale model were conformed to
home-made capsule. This result expressed that free diffusion
was the main drug release mechanism. The “n”of Ritger-
Peppas model were 0.8327and 0.7386 of home-made and
Harnual® respectively. From the result, we can conclude that
both free diffusion and relaxation plays the role in the drug
release of Harnual® and self-made pellets. This result is
identical with the above conclusion.3.11. The results of stability study
As shown in Table 5, the contents, related substances of
samples with high temperature, high humidity and light at 5 d
and 10 d are both unchanged. However, the dissolution
release of samples with high humidity (RH 92.5%) at 10 d was
decreased significantly. This indicated that the permeability
of the coatingmembrane was influenced seriously. Therefore,
the pellets must be kept away from moisture during the
package and transportation and stored in a cool and dark
place away from moisture.Related
substances (%)
(after the main drug)
Content
(%)
Accumulative release (%)
2 3 5
19.12 100.00 20.83 57.40 74.24
32.76 99.41 17.61 59.75 73.85
33.31 98.39 20.02 68.20 79.63
18.20 98.81 18.05 61.67 72.83
42.88 99.79 20.00 68.66 80.90
17.28 99.68 18.16 64.96 80.13
27.05 100.84 15.80 56.72 73.61
19.05 100.50 14.40 57.59 76.08
33.11 100.30 14.84 40.49 57.63
17.88 99.59 22.96 65.06 80.40
33.99 99.51 23.47 64.45 82.41
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 3 1e3 9 394. Conclusions
TSH SR pellets capsule was successfully manufactured in a
laboratory-scale. During the preparation process, the param-
eters of equipments must be well controlled to promise the
quality of pellets. The drug release behavior of two dosage
forms were different through the analysis of release models
and SEM experiment. To testify the fungibility of home-made
capsules, the experiment of bioequivalence may be needed to
carry out.r e f e r e n c e s
[1] O'Leary MP. Tamsulosin: current clinical experience. Urology
2001;58:42e48.
[2] Chapple C, Andersson KE. Tamsulosin: an overview. World
J.Urol 2002;19:397e404.
[3] Marvola M, Nyk€anen P, Rautio S, et al. Enteric polymers as
binders and coating materials in multiple-unit site specific
drug delivery systems. Eur J Pharm Sci 1999;7:259e267.
[4] Kim MS, Jun SW, Lee S, et al. The influence of surelease and
sodium alginate on the in-vitro release of tamsulosin
hydrochloride in pellet dosage form. J Pharm Pharmacol
2005;57:735e742.
[5] Kim MS, Park GD, Jun SW, et al. Controlled release
tamsulosin hydrochloride from alginate beads with waxy
materials. J Pharm Pharmacol 2005;57:1521e1528.
[6] Maeda A, Shinoda T, Ito N, et al. Evaluating tamsulosin
hydrochloride-released microparticles prepared using
single-step matrix coating. Int J Pharm 2011;408:84e90.
[7] Zhang X, Tang X, Yang R. Development of a tamsulosin
hydrochloride controlled-release capsule consisting of two
different coated pellets. Drug Dev Ind Pharm 2009;35:26e33.
[8] Kim JS, Kim MS, Park HJ, et al. Statistical optimization of
tamsulosin hydrochloride controlled release pellets coated
with the blend of HPMCP and HPMC. Chem Pharm Bull
2007;55:936e939.
[9] Siepmann F, Siepmann J, Walther M, et al. Polymer blends for
controlled release coatings. J Control Release 2008;125:1e15.[10] Lecomtea F, Siepmanna J, Waltherb M, et al. Blends of enteric
and GIT-insoluble polymers used for film coating:
physicochemical characterization and drug release patterns.
J Control Release 2003;89:457e471.
[11] Cuppok Y, Muschert S, Marucci M, et al. Drug release
mechanisms from Kollicoat SR: Eudragit NE coated pellets.
Int J Pharm 2011;409:30e37.
[12] Raval MK, Ramani RV, Sheth NR, et al. Formulation and
evaluation of sustained-release enteric-coated pellets of
budesonide for intestinal delivery. Int J Pharm Investig
2013;3:203e211.
[13] Prasad MB, Vidyadhara S, Sasidhar RLC, et al. Development
and evaluation of diltiazem hydrychloride controlled-release
pellets by fluid bed coating process. J Adv Pharm Technol Res
2013;4:101e107.
[14] USP 23: Tamsulosin hydrochloride sustained-release
capsule.
[15] Moore JW, Flanner HH. Mathematical comparison of
dissolution profiles. Pharma Tech 1996;20:64e74.
[16] Siepmann F, Wahle C, Leclercq B, et al. pH-sensitive film
coatings: towards a better understanding and facilitated
optimization. Eur J Pharm Biopharm 2008;68:2e10.
[17] Nakamura K, Nara E, Akiyama Y. Development of an oral
sustained release drug delivery system utilizing pH-
dependent swelling of carboxyvinyl polymer. J Control
Release 2006;111:309e315.
[18] Yang QW, Flament MP, Siepmann F, et al. Curing of aqueous
polymeric film coatings: importance of the coating level and
type of plasticizer. Eur J Pharm Biopharm 2010;74:362e370.
[19] Samuelov Y, Donbrow M, Friedman M. Sustained release of
drugs from ethylcellulose polyethylene glycol films and
kinetics of drug release. J Pharm Sci 1979;68:325e329.
[20] Lapidus H, Lordi NG. Some factors affecting the release of a
water-soluble drug from a compressed hydrophilic matrix.
J Pharm Sci 1966;55:840e843.
[21] Higuchi T. Rate of release of medicaments from ointment
bases containing drugs in suspension. J Pharm Sci
1961;50:874e875.
[22] Baker RW, Lonsdale HK. Controlled release of biologically
active agents. In: Tanquary AC, Lacey RE, editors. New York:
Plenum; 1974. p. 15e71.
[23] Ritger PL, Peppas NA. A simple equation for description of
solute release II. Fickian and anomalous release from
swellable devices. J Control Release 1987;5:37e42.
